Yuan Zhong-Yu | Medical Oncology | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Yuan Zhong-Yu

Title: Professor and Doctoral Advisor

Email: yuanzhy@sysucc.org.cn

Phone:

Profile

Professor Zhong-Yu Yuan has been engaged in clinical work and medical oncology research for more than 20 years. He has extensive experience and expertise in the field of breast cancer. His primary interest is the treatment and research of breast cancer treatment, particularly, triple negative breast cancer. Professor Yuan has published more than 50 clinical papers in top-tier journals like: JAMA, Lancet Oncology, CCR, JNCI, and has been invited to present his research results at ASCO, St. Gallen, and other international conferences. As a Member of the Good Clinical Practice in SYUCC, he has initiated many ITT and SFDA approved clinical trials.

Interests

Medical oncology and translational research focused on triple negative breast cancer. The development of novel drugs for breast cancer, and the conducting of Phase I and II clinical trials to test these drugs.

Education

Bachelor's and Master's at Anhui Medical University in 1989, and 2000, respectively. Doctor at Sun Yat-sen University since 2003.

Publications

Selected Publications
1. Hua X*, Bi XW*, Zhao JL*, Shi YX*, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, Liu XM, Xu F, Guo Y, Xia W, Hong RX, Jiang KK, Xue C, An X, Zhong YY, Wang SS*, Huang JJ*, Yuan ZY*. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res. 2022; 28(4):637-645.

2. Wang X*, Wang SS*, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY*; South China Breast Cancer Group (SCBCG). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021; 325(1):50-58.

3. Su Y*, Huang J*, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y, Li J, Gao Y, Shi W, Wang X, Peng R, Xu F, An X, Xue C, Xia W, Hong R, Zhong Y, Lin Y, Huang H, Zhang A, Zhang L, Cai L, Zhang J, Yuan Z*. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. J Natl Cancer Inst. 2020;112(1):55-62.

4. Su Y*, Zhang Y*, Hua X, Huang J, Bi X, Xia W, Wang X, Huang Z, Song C, Zhong Y, Shi Y, Wang S; Fan W*, Yuan Z*. High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study. Adv Med Oncol. 2021; 13: 1–9.

5. Duan FF, Li JP, Huang JJ, Hua X, Song CG, Wang L, Bi XW, Xia W, Yuan ZY. Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer. Front Cell Dev Biol. 2021;9:770115.

6. Hua X*, Huang X*, Huang ZZ*, Song CG, Deng JP, Long ZQ, Lin HX, Yuan ZY*. Establishment of prognostic nomograms based on skeletal muscle index and serum biomarker in breast cancer patients receiving radiotherapy. Clin Transl Med. 2020;10(2):e115.

7. Wang X*, Bi X*, Huang Z*, Huang J, Xia W, Shi W, Yuan Z*. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer. Endocr Relat Cancer. 2020; 27:199-208.

8. Wang X*, Li J*, Shi W, Huang Z, Xia W, Huang J, Su Y, Wang S, Shi Y, Bi X*, Yuan Z*. Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. Oncologist. 2020; 25(10):e1439-45.

9. Xiong Z*, Ye L*, Zhenyu H*, Li F, Xiong Y, Lin C, Wu X, Deng G, Shi W, Song L, Yuan Z*, Wang X*. ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1. Mol Oncol. 2018; 12(6):896-912.

10. Cui Y*, Ma W*, Lei F*, Li Q, Su Y, Lin X, Lin C, Zhang X, Ye L, Wu S, Li J, Yuan Z*, Song L*. Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling. J Pathol. 2016;239:297–308.

Updated June 2022 by International Office, Sun Yat-sen University Cancer Center

Our Experts